📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. (2015)

First Author: Mead AJ

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjh.13379

PubMed Identifier: 25824940

Publication URI: http://europepmc.org/abstract/MED/25824940

Type: Journal Article/Review

Volume: 170

Parent Publication: British journal of haematology

Issue: 1

ISSN: 0007-1048